Abstract
Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Adolescent Psychiatry
Title: The Therapeutic Community for the Adolescent Substance Abuser
Volume: 1 Issue: 2
Author(s): Gregory C. Bunt and Britta Muehlbach
Affiliation:
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Abstract: Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Export Options
About this article
Cite this article as:
C. Bunt Gregory and Muehlbach Britta, The Therapeutic Community for the Adolescent Substance Abuser, Adolescent Psychiatry 2011; 1 (2) . https://dx.doi.org/10.2174/2210676611101020122
DOI https://dx.doi.org/10.2174/2210676611101020122 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Animal Models for Investigating Benign Essential Blepharospasm
Current Neuropharmacology Role of Metal Ions in the Aβ Oligomerization in Alzheimers Disease and in Other Neurological Disorders
Current Alzheimer Research P2X4 Receptors of Microglia in Neuropathic Pain
CNS & Neurological Disorders - Drug Targets The Effect of Cyberspace-Based Education on the Well-Being of Caregivers of Elderly People with Dementia
Current Aging Science Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease
Mini-Reviews in Medicinal Chemistry Bibliometrics and Visualization of the Mechanisms of Parkinson's Diseases Based on Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenetics in Type 2 Diabetes: Polymorphisms in Candidate Genes Affecting Responses to Antidiabetic Oral Treatment
Current Pharmacogenomics Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Conference Report
CNS & Neurological Disorders - Drug Targets Impact of MRI-based Segmentation Artifacts on Amyloid- and FDG-PET Quantitation
Current Alzheimer Research High Risk Driving in Treated and Untreated Youth with Attention Deficit Hyperactivity Disorder: Public Health Implications
Adolescent Psychiatry Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews N-Dealkylation of Arylpiperazine Derivatives: Disposition and Metabolism of the 1-Aryl-Piperazines Formed
Current Drug Metabolism Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders
Current Drug Targets Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Macrophages in Inflammation
Current Drug Targets - Inflammation & Allergy Urine Comprehensive Drug Screen, Low Birth Weight and Withdrawal Symptoms in a Neonatal Unit: A Case Control Study
Current Clinical Pharmacology Human Fetal Pigmented Ciliary Epithelium Stem Cells have Regenerative Capacity in the Murine Retinal Degeneration Model of Laser Injury
Current Neurovascular Research Novel Natural Agents from Lamiaceae Family: An Evaluation on Toxicity and Enzyme Inhibitory Potential Linked to Diabetes Mellitus
Current Bioactive Compounds